ARDS Clinical Network Prospective, Randomized, Blinded, Placebo-controlled, Multi-center Trial of Omega-3 Fatty Acid, Gamma-Linolenic Acid, and Anti-Oxidant Supplementation in the Management of Acute Lung Injury or Acute Respiratory Distress Syndrome ARDS (OMEGA)
Study Type: Clinical Trial
Prepared on November 17, 2009
Consent: Proprietary Consent
Commercial Use Restrictions: No
Collection Type: Proprietary Study - See bottom of this webpage for request information
This study was a prospective randomized controlled study of an omega 3 and antioxidant supplement added to usual feeding. Patients were followed to the earlier of 60 days or hospital discharge; vital status was ascertained at 180 days. The primary efficacy variable was ventilator-free days to study day 28. This study was stopped for futility after 272 patients. The OMEGA study was conducted on a subset of EDEN patients as a part of a factorial design.